Body mass index and risk of BPH: a meta-analysis
Shufeng Wang(Southwest University), Liping Xie(First Affiliated Hospital Zhejiang University), Xiangyi Zheng(Tianjin University), Qinan Mao(First Affiliated Hospital Zhejiang University), Xiao Wang(Qingdao University), Jian Wu(Sun Yat-sen University), Yiwei Lin(First Affiliated Hospital Zhejiang University)
Cited by 80
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276